# Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

> **NCT04323189** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 20 (estimated)

## Conditions studied

- Genetics Disease
- Type2 Diabetes
- Heart Failure

## Interventions

- **DRUG:** Sitagliptin 100mg
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT04323189
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-26
- **Primary completion:** 2025-02-27
- **Final completion:** 2026-02-28
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04323189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04323189, "Effects of Sitagliptin in Individuals With Genetically Decreased DPP4". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04323189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*